{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:41:58Z","timestamp":1787168518004,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100016077","name":"Dongguan Science and Technology Bureau","doi-asserted-by":"crossref","award":["20221800905762"],"award-info":[{"award-number":["20221800905762"]}],"id":[{"id":"10.13039\/501100016077","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Brain injury in preterm infants (BIPI) remains a significant clinical challenge with limited diagnostic biomarkers. This study aimed to investigate urinary 6-sulfatoxymelatonin (6-SMT) levels as a potential noninvasive biomarker for brain injury in very preterm infants. A prospective cohort study was conducted with 127 very preterm infants admitted to our hospital from January to December 2024. Infants were categorized into brain-injury and control group based on neuroimaging findings. Urinary 6-SMT concentrations were measured on postnatal days 1, 3, and 7 using ELISA. Clinical parameters and perinatal risk factors were evaluated. Receiver operating characteristic (ROC) curve analysis was used to assess diagnostic efficacy, and conditional logistic regression analysis was performed to evaluate the association between urinary 6-SMT levels and brain injury. Compared with the control group (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200997), infants with brain injury (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200930) exhibited significantly lower gestational age (GA: 29.36 vs. 30.43 weeks,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.028) and birth weight (BW: 1.21 vs. 1.34\u00a0kg,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.030), significantly lower rates of acidosis (10.0% vs. 12.4%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.023) and antenatal magnesium sulfate (MgSO\u2084) exposure (30.0% vs. 60.8%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003), and significantly higher rates of early infection (46.7% vs. 21.6%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.007) and asphyxia (30.0% vs. 1.0%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.014). Crucially, urinary 6-SMT levels were markedly lower in the brain injury group on all measurement days (day 1: 558.51 vs. 813.86 pg\/mL,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.015; day 3: 722.62 vs. 938.48 pg\/mL,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001; Day 7: 796.81 vs. 1034.48 pg\/mL,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.014). ROC analysis identified day 3 urinary 6-SMT (cut-off 762.46 pg\/mL) as the best single marker (AUC\u2009=\u20090.714, sensitivity 73.2%, specificity 70.0%), while a combined model integrating levels from days 1, 3, and 7 achieved superior diagnostic performance (AUC\u2009=\u20090.764, sensitivity 78.4%, specificity 66.7%). Urinary 6-SMT levels progressively increased during the first postnatal week and correlated positively with GA and BW on days 1 and 3, but correlations weakened by day 7. After 1:1 matching on GA and BW, conditional logistic regression analysis confirmed a significant protective association between higher day 3 urinary 6-SMT levels and reduced brain injury risk (adjusted OR\u2009=\u20090.996,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.004). Reduced urinary 6-SMT concentrations in very preterm neonates are significantly associated with brain injury. Serial urinary 6-SMT measurements, particularly when combined across multiple time points, demonstrate promising diagnostic potential as a noninvasive biomarker for BIPI. These findings suggest that melatonin deficiency may contribute to the pathophysiology of preterm brain injury and warrant further investigation for clinical translation.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-42005-0","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T18:56:55Z","timestamp":1772218615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Urinary 6-sulfatoxymelatonin as a predictive biomarker for brain injury in very preterm infants"],"prefix":"10.1038","volume":"16","author":[{"given":"Yan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincheng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhen","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minxu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"6","key":"42005_CR1","doi-asserted-by":"publisher","first-page":"e2022057442","DOI":"10.1542\/peds.2022-057442","volume":"150","author":"P Rees","year":"2022","unstructured":"Rees, P. et al. Preterm Brain Injury and Neurodevelopmental Outcomes: A Meta-analysis. Pediatrics 150 (6), (2022).","journal-title":"Pediatrics"},{"issue":"8","key":"42005_CR2","doi-asserted-by":"publisher","first-page":"e209264","DOI":"10.1212\/WNL.0000000000209264","volume":"102","author":"RE Grunau","year":"2024","unstructured":"Grunau, R. E. & Miller, S. P. Size and Location of Preterm Brain Injury and Associations With Neurodevelopmental Outcomes. Neurology 102 (8), e209264 (2024).","journal-title":"Neurology"},{"key":"42005_CR3","doi-asserted-by":"publisher","first-page":"1339304","DOI":"10.3389\/fimmu.2024.1339304","volume":"15","author":"TT Joseph","year":"2024","unstructured":"Joseph, T. T., Schuch, V., Hossack, D. J., Chakraborty, R. & Johnson, E. L. Melatonin: the placental antioxidant and anti-inflammatory. Front. Immunol. 15, (2024).","journal-title":"Front. Immunol."},{"issue":"1","key":"42005_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/antiox14010025","volume":"14","author":"M Sieminski","year":"2024","unstructured":"Sieminski, M., Reimus, M., Ka\u0142as, M. & St\u0119pniewska, E. Antioxidant and Anti-Inflammatory Properties of Melatonin in Secondary Traumatic Brain Injury. Antioxid. (Basel). 14 (1), 25 (2024).","journal-title":"Antioxid. (Basel)"},{"issue":"6","key":"42005_CR5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3390\/antiox9060477","volume":"9","author":"G D\u2019Angelo","year":"2020","unstructured":"D\u2019Angelo, G., Chimenz, R., Reiter, R. J. & Gitto, E. Use of Melatonin in Oxidative Stress Related Neonatal Diseases. Antioxid. (Basel). 9 (6), 477 (2020).","journal-title":"Antioxid. (Basel)"},{"issue":"2","key":"42005_CR6","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s12015-024-10819-y","volume":"21","author":"K Mirnia","year":"2025","unstructured":"Mirnia, K. et al. Enhancing Late Retinopathy of Prematurity Outcomes with Fresh Bone Marrow Mononuclear Cells and Melatonin Combination Therapy. Stem Cell. Rev. Rep. 21 (2), 466\u2013476 (2025).","journal-title":"Stem Cell. Rev. Rep."},{"issue":"3","key":"42005_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1515\/revneuro-2023-0126","volume":"35","author":"S Perrone","year":"2023","unstructured":"Perrone, S. et al. Nonnis Marzano F. Hypoxic ischemic brain injury: animal models reveal new mechanisms of melatonin-mediated neuroprotection. Rev. Neurosci. 35 (3), 331\u2013339 (2023).","journal-title":"Rev. Neurosci."},{"issue":"4","key":"42005_CR8","doi-asserted-by":"publisher","first-page":"e12962","DOI":"10.1111\/jpi.12962","volume":"76","author":"R Pang","year":"2024","unstructured":"Pang, R. et al. Melatonin reduces brain injury following inflammation-amplified hypoxia-ischemia in a translational newborn piglet study of neonatal encephalopathy. J. Pineal Res. 76 (4), e12962 (2024).","journal-title":"J. Pineal Res."},{"key":"42005_CR9","doi-asserted-by":"publisher","first-page":"101614","DOI":"10.1016\/j.smrv.2022.101614","volume":"63","author":"W Braam","year":"2022","unstructured":"Braam, W. & Spruyt, K. Reference intervals for 6-sulfatoxymelatonin in urine: A meta-analysis. Sleep. Med. Rev. 63, 101614 (2022).","journal-title":"Sleep. Med. Rev."},{"key":"42005_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-1-0716-2593-4_4","volume":"2550","author":"MA St Hilaire","year":"2022","unstructured":"St Hilaire, M. A. & Lockley, S. W. Measuring Urinary 6-Sulphatoxymelatonin in Humans. Methods Mol. Biol. 2550, 21\u201328 (2022).","journal-title":"Methods Mol. Biol."},{"issue":"4","key":"42005_CR11","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0022-3476(78)80282-0","volume":"92","author":"L-A Papile","year":"1978","unstructured":"Papile, L-A., Burstein, J., Burstein, R. & Koffler, H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J. Pediatr. 92 (4), 529\u2013534 (1978).","journal-title":"J. Pediatr."},{"issue":"1","key":"42005_CR12","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1542\/peds.2013-1288","volume":"132","author":"LS De Vries","year":"2013","unstructured":"De Vries, L. S., Van Haastert, I-C., Benders, M. J. & Groenendaal, F. Myth versus reality: the meaning of periventricular echodensities on cranial ultrasound. Pediatrics 132 (1), 180\u2013185 (2013).","journal-title":"Pediatrics"},{"issue":"12","key":"42005_CR13","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.4103\/1673-5374.241441","volume":"13","author":"C Chollat","year":"2018","unstructured":"Chollat, C. & Marret, S. Magnesium sulfate and fetal neuroprotection: overview of clinical evidence. Neural Regen Res. 13 (12), 2044\u20132049 (2018).","journal-title":"Neural Regen Res."},{"issue":"12","key":"42005_CR14","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1111\/aogs.14673","volume":"102","author":"S Hellstr\u00f6m","year":"2023","unstructured":"Hellstr\u00f6m, S. et al. A follow up on the feasibility after national implementation of magnesium sulfate for neuroprotection prior to preterm birth. Acta Obstet. Gynecol. Scand. 102 (12), 1741\u20131748 (2023).","journal-title":"Acta Obstet. Gynecol. Scand."},{"issue":"1","key":"42005_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13052-024-01744-4","volume":"50","author":"S Cheng","year":"2024","unstructured":"Cheng, S., Sun, X., Li, Y. & Dong, Y. Evaluation of SBDP145, melatonin, sLOX-1, HMGB1 and HIF-1\u03b1 in preterm infants with brain injury. Ital. J. Pediatr. 50 (1), 172 (2024).","journal-title":"Ital. J. Pediatr."},{"issue":"9","key":"42005_CR16","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.3390\/ijms20092077","volume":"20","author":"V Biran","year":"2019","unstructured":"Biran, V. et al. Melatonin Levels in Preterm and Term Infants and Their Mothers. Int. J. Mol. Sci. 20 (9), 2077 (2019).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"42005_CR17","doi-asserted-by":"publisher","first-page":"e12932","DOI":"10.1111\/jpi.12932","volume":"76","author":"F Garofoli","year":"2024","unstructured":"Garofoli, F. et al. Fate of melatonin orally administered in preterm newborns: Antioxidant performance and basis for neuroprotection. J. Pineal Res. 76 (1), e12932 (2024).","journal-title":"J. Pineal Res."},{"issue":"1","key":"42005_CR18","first-page":"118","volume":"12","author":"B Hakiminia","year":"2022","unstructured":"Hakiminia, B., Alikiaie, B., Khorvash, F. & Mousavi, S. Targeting Mitochondrial and Brain Injury Markers in Acquired Brain Injuries:A Randomized, Double-Blind, Placebo-Controlled Study with Melatonin. Adv. Pharm. Bull. 12 (1), 118\u2013127 (2022).","journal-title":"Adv. Pharm. Bull."},{"issue":"6","key":"42005_CR19","doi-asserted-by":"publisher","first-page":"108299","DOI":"10.1016\/j.jstrokecerebrovasdis.2025.108299","volume":"34","author":"Y Liu","year":"2025","unstructured":"Liu, Y. et al. Melatonin attenuates brain edema via the PI3K\/Akt\/Nrf2 pathway in rats with cerebral ischemia-reperfusion injury. J. Stroke Cerebrovasc. Dis. 34 (6), 108299 (2025).","journal-title":"J. Stroke Cerebrovasc. Dis."},{"issue":"4","key":"42005_CR20","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.12669\/pjms.39.4.7252","volume":"39","author":"H Hou","year":"2023","unstructured":"Hou, H. & Li, X. Clinical changes of serum melatonin and ICAM-1 levels in patients with basal ganglia hypertensive intracerebral hemorrhage. Pak J. Med. Sci. 39 (4), 1024\u20131028 (2023).","journal-title":"Pak J. Med. Sci."},{"issue":"8","key":"42005_CR21","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1007\/s00431-024-05632-1","volume":"183","author":"C S\u00e1nchez-Borja","year":"2024","unstructured":"S\u00e1nchez-Borja, C. et al. Lower plasma melatonin levels in non-hypoxic premature newborns associated with neonatal pain. Eur. J. Pediatr. 183 (8), 3607\u20133615 (2024).","journal-title":"Eur. J. Pediatr."},{"issue":"5\u20136","key":"42005_CR22","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s00508-022-02109-9","volume":"136","author":"H Pavlyshyn","year":"2024","unstructured":"Pavlyshyn, H., Sarapuk, I. & Kozak, K. Peculiarities of melatonin levels in preterm infants. Wien Klin. Wochenschr. 136 (5\u20136), 146\u2013153 (2024).","journal-title":"Wien Klin. Wochenschr"},{"issue":"4","key":"42005_CR23","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1159\/000320643","volume":"99","author":"M Cetinkaya","year":"2011","unstructured":"Cetinkaya, M. et al. Possible neuroprotective effects of magnesium sulfate and melatonin as both pre- and post-treatment in a neonatal hypoxic-ischemic rat model. Neonatology 99 (4), 302\u2013310 (2011).","journal-title":"Neonatology"},{"key":"42005_CR24","doi-asserted-by":"publisher","first-page":"680899","DOI":"10.3389\/fnsyn.2021.680899","volume":"13","author":"NA Elsayed","year":"2021","unstructured":"Elsayed, N. A., Boyer, T. M. & Burd, I. Fetal Neuroprotective Strategies: Therapeutic Agents and Their Underlying Synaptic Pathways. Front. Synaptic Neurosci. 13, 680899 (2021).","journal-title":"Front. Synaptic Neurosci."},{"key":"42005_CR25","doi-asserted-by":"publisher","first-page":"1201699","DOI":"10.3389\/fphys.2023.1201699","volume":"14","author":"Y Kitase","year":"2023","unstructured":"Kitase, Y. et al. Chorioamnionitis disrupts erythropoietin and melatonin homeostasis through the placental-fetal-brain axis during critical developmental periods. Front. Physiol. 14, 1201699 (2023).","journal-title":"Front. Physiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42005-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42005-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42005-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T21:02:01Z","timestamp":1775250121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42005-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["42005"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-42005-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"3 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study protocol was reviewed and approved by the Ethics Committee of the Dongguan Maternal and Child Health Care Hospital Ethics Committee, approval number 2022036.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from their parent or legal guardian of all participating very preterm infants prior to their inclusion in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The analysis results presented in this article and supplementary tables are fully accessible within the paper and its online supplements. The datasets generated and\/or analyzed during the current study are not publicly available due to patient confidentiality and privacy restrictions imposed by the Ethics Committee and relevant regulations. However, de-identified data may be made available from the corresponding author upon reasonable request and subject to approval by the Ethics Committee.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"11254"}}